These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18556715)

  • 1. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 2. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
    Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
    Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rimonabant. Risk of depression has not been finally clarified].
    Kreutzkamp B
    Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
    [No Abstract]   [Full Text] [Related]  

  • 9. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rimonabant, obesity and diabetes.
    Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
    Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
    Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
    [No Abstract]   [Full Text] [Related]  

  • 12. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
    JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rimonabant: obituary for a wonder drug.
    Boekholdt SM; Peters RJ
    Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
    [No Abstract]   [Full Text] [Related]  

  • 15. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
    Christopoulou FD; Kiortsis DN
    J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleiotropic effects of rimonabant: clinical implications.
    Després JP
    Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rimonabant (Acomplia)].
    Duh D; Vanddevijver A
    J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
    [No Abstract]   [Full Text] [Related]  

  • 18. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).
    Boesten JE; Kaper J; Stoffers HE; Kroon AA; van Schayck OC
    Fam Pract; 2012 Oct; 29(5):521-7. PubMed ID: 22389428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prescription of rimonabant in the early stage of pregnancy?].
    Picksak G; Stichtenoth DO
    Med Monatsschr Pharm; 2008 Mar; 31(3):107-8. PubMed ID: 18429532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sleep disorders associated with treatment with rimonabant].
    Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
    Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.